Efficacy And Safety Of Denosumab And Teriparatide Treatment For Osteoporosis: A Systematic Review And Meta-Analysis

Tao Wang,Zhaopeng Xuan,Ruijun Li,Liangsong Song,Yichen Dou,Jingyan Ren,Xueyuan Jia,Laijin Lu

2017-01-01

Abstract:Purpose: It may be promising to combine denosumab with teriparatide for the treatment of osteoporosis. However, the results remain controversial. We conduct a systematic review and meta-analysis to evaluate the efficacy and safety of combination treatment (denosumab and teriparatide) versus teriparatide treatment in patients with osteoporosis. Methods: Medline, SCOPUS, Google Scholar, EMBASE, Springer, and Science Direct are searched electronically. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) regarding the combination treatment versus teriparatide treatment for osteoporosis are included. Two investigators independently search articles, extracted data, and assess the quality of included studies. The primary outcome is the increase in spine bone mineral density (BMD) and hip BMD. Meta-analysis is performed using the fixed-effect model or random-effect model when appropriate. Results: Four studies are included in this meta-analysis. Overall, compared with teriparatide treatment, combination treatment of denosumab and teriparatide significantly increases hip BMD (mean difference = 3.59%; 95% CI = 2.23% to 4.95%; P<0.00001), femoral neck BMD (mean difference = 3.29%; 95% CI = 2.08% to 4.50%; P<0.00001) and radius BMD (mean difference = 3.35%; 95% CI = 2.59% to 4.11%; P<0.00001), but fails to increase spine BMD (mean difference = 1.65%; 95% CI = -1.27% to 4.56%; P = 0.27). Conclusion: Our meta-analysis suggests that combination treatment of denosumab and teriparatide shows an important ability to increase the BMD in patients with osteoporosis. Combination treatment should be recommended to treat osteoporosis, but with caution due to clinical heterogeneity.